You've been automatically redirected here from, which is now part of Proteintech Group. Click here to dismiss this alert.
Recombinant antibodies

Antibodies have been a critical reagent in biological research for decades.  Recently, due to issues surrounding scientific reproducibility, there is a growing need for antibodies with extraordinary specificity and minimal lot variability. Until recently, this was not possible. However, recent advances in molecular biology and screening have enabled production of genetically defined, recombinant antibodies.

Due to their low lot-to-lot variability and high specificity, recombinant antibodies are being touted as the future of antibodies in research paving the way for researchers to have unrivalled reproducibility and trust in these reagents.

What are recombinant antibodies?

There are many methods of producing recombinant antibodies. At Proteintech, recombinant antibodies are monoclonal antibodies that have been produced by in vitro cloning of the antibody heavy and light chain DNA sequences from the B cells or plasma cells of immunized animals. Unlike traditional monoclonal antibodies produced from hybridomas, the recombinant vectors are introduced into expression hosts (e.g. E. coli) to then produce the antibodies. This recombinant technology results in almost no lot-to-lot variability, removing the risk of genetic drift that can result in variations in of monoclonal antibodies.

recombinant antibodies vs traditional antibodies


View all recombinant antibodies


to top